Regents of the University of California’s RAPT Therapeutics RAPT Stock Holding History

Regents of the University of California’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,366	Closed	-$692K	–	33
2022 Q4	$692K	Sell	4,366 -10,442	-71%	-$1.67M	0.13%	20
2022 Q3	$2.85M	Sell	14,808 -40,644	-73%	-$7.69M	0.58%	9
2022 Q2	$8.1M	Hold	55,452	–	–	1.62%	6
2022 Q1	$9.76M	Hold	55,452	–	–	1.47%	6
2021 Q4	$16.3M	Sell	55,452 -20,631	-27%	-$5.51M	2.28%	5
2021 Q3	$18.9M	Sell	76,083 -21,741	-22%	-$5.75M	2.23%	6
2021 Q2	$24.9M	Sell	97,824 -27,176	-22%	-$5.08M	3.18%	3
2021 Q1	$22.2M	Sell	125,000 -15,280	-11%	-$2.52M	2.89%	4
2020 Q4	$22.2M	Sell	140,280 -32,308	-19%	-$7.03M	3.2%	4
2020 Q3	$44.5M	Sell	172,588 -23,942	-12%	-$5.31M	6.18%	3
2020 Q2	$45.6M	Buy	+196,530	New	+$30.4M	6.4%	3

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Regents of the University of California's RAPT Position: Q1 2023 in Review

Regents of the University of California sold out of RAPT Therapeutics (RAPT) in Q1 2023, closing a stake of 4,366 shares — an estimated $692K sold.

Regents of the University of California first reported a position in RAPT in Q2 2020 and held it in 11 quarters. The position peaked at $45.6M in Q2 2020. 106 funds tracked by Wall St. Rank hold RAPT as of Q1 2023.

Regents of the University of California reported no remaining RAPT Therapeutics position as of Q1 2023 after selling out during the quarter.
Regents of the University of California sold 4,366 RAPT Therapeutics shares in Q1 2023, an estimated $692K.
Regents of the University of California first reported a position in RAPT Therapeutics in Q2 2020 and held it in 11 quarters.
Regents of the University of California's RAPT Therapeutics position peaked at $45.6M in Q2 2020.
106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2023.

Based on Regents of the University of California's 13F filing for Q1 2023, filed 5 May 2023.